What is Cagrilintide?
Cagrilintide is a synthetic, long-acting analog of human amylin, engineered with a fatty-acid modification to extend its stability profile relative to the native hormone and studied as a dual agonist at the amylin receptor complex and the calcitonin receptor (CTR). It is catalogued under CAS number 1415456-99-3, with a molecular formula of C₁₉₄H₃₁₂N₅₄O₅₉S₂ and a molecular weight of approximately 4409.01 g/mol. The compound is produced through solid-phase peptide synthesis with a site-specific lipidation step, supplied as a lyophilized powder, and is intended solely for laboratory research purposes, not for human use.
Amino Line catalogues Cagrilintide within its structural characterization line — compounds selected less for a single signaling pathway and more for what their synthesis and analytical validation demonstrate about large, lipidated peptide manufacturing. A 37-residue amylin backbone carrying a fatty-acid conjugation site is a materially more complex synthesis target than the short heritage fragments Amino Line has traditionally catalogued, and the same methods-first characterization standard — HPLC purity confirmation, mass spectrometry identity verification, batch-specific documentation — applies to it without modification. This article covers Cagrilintide's molecular architecture, the amylin receptor system it is studied against, and the analytical methods used to validate research-grade material.
Understanding Cagrilintide as a research compound requires first understanding amylin, the endogenous hormone it is derived from, and the receptor complex the analog is designed to engage.
What is amylin, and how does Cagrilintide relate to it?
Amylin, also called islet amyloid polypeptide (IAPP), is a 37-amino-acid peptide hormone co-secreted with insulin from pancreatic beta cells in response to nutrient stimuli in studied model systems. Structurally, native amylin carries an intramolecular disulfide bond between cysteine residues near its N-terminus and a C-terminal amidation, both of which are relevant to its receptor-binding conformation. Native amylin has a short functional half-life in biological systems and a documented tendency toward self-aggregation into amyloid fibrils, a property that has made native amylin difficult to work with directly in extended research protocols.
Cagrilintide is studied as an engineered response to both limitations. The fatty-acid modification promotes reversible albumin binding, a stabilization strategy structurally analogous to the lipidation approach used in long-acting GLP-1 receptor agonist analogs, and is associated in published pharmacokinetic research with a substantially extended half-life relative to native amylin in model systems. The modification is also reported in the analog-design literature to reduce the self-aggregation propensity that complicates native amylin handling, an effect relevant to both research reproducibility and manufacturing consistency.
Because Cagrilintide retains the core amylin sequence architecture required for receptor engagement while addressing amylin's principal experimental liabilities, it is catalogued and studied as a research proxy for amylin receptor biology broadly, rather than as a structurally unrelated synthetic novelty.
What is the molecular structure of Cagrilintide?
Cagrilintide has a molecular weight of approximately 4409.01 g/mol and a molecular formula of C₁₉₄H₃₁₂N₅₄O₅₉S₂, reflecting a 37-amino-acid peptide backbone modified with a fatty-acid conjugate attached through a linker chemistry designed to project the lipid moiety away from the receptor-binding surface. This design objective — preserving the receptor-engaging face of the peptide while adding a large, non-native chemical group elsewhere on the molecule — is a defining engineering feature of lipidated peptide analogs generally, and Cagrilintide's synthesis route is evaluated in research contexts partly for how well it achieves that separation.
The peptide is produced through solid-phase synthesis, with the lipidation conjugation typically performed as a distinct downstream step from the core peptide chain assembly. This two-stage synthesis — linear peptide construction followed by site-specific fatty-acid attachment — is more analytically demanding to validate than single-stage peptide synthesis, because purity and identity confirmation must account for both the peptide backbone and the conjugation site. Research-grade Cagrilintide is characterized by HPLC purity analysis capable of resolving under-lipidated or over-lipidated byproducts from the target conjugate, alongside mass spectrometry identity confirmation of the full-mass lipidated species. The compound is supplied in lyophilized form as a white to off-white powder.
What is the amylin receptor complex, and why is it a research target?
The amylin receptor is not a single, independently encoded gene product. It is a complex formed by the calcitonin receptor (CTR), a class B G-protein-coupled receptor, in association with one of three receptor activity-modifying proteins (RAMP1, RAMP2, or RAMP3). RAMP association reconfigures the ligand-binding pharmacology of CTR, producing a receptor complex — designated AMY1, AMY2, or AMY3 depending on which RAMP is present — with substantially higher affinity for amylin than CTR alone exhibits.
This receptor architecture makes amylin receptor research inherently a study of protein-protein complex formation as much as ligand-receptor binding. Published structural and pharmacological research has examined how RAMP association alters the CTR extracellular domain's binding pocket geometry, and cryo-electron microscopy studies of the amylin receptor complex bound to amylin-class peptides have provided atomic-resolution detail of this ligand-receptor-RAMP interface. Cagrilintide, as a stabilized amylin analog, is used in this research context to generate reproducible, extended-duration binding and signaling data that native amylin's aggregation tendency and short half-life make difficult to obtain.
Because Cagrilintide retains affinity for CTR independent of RAMP association in addition to the RAMP-associated amylin receptor complexes, it is described in the pharmacology literature as a dual agonist — engaging both the amylin receptor complex and calcitonin receptor directly. This dual engagement profile is a distinguishing pharmacological feature relative to receptor-selective research tools and is itself a subject of ongoing structural and signaling characterization.
How is Cagrilintide characterized and validated at the analytical level?
Analytical validation of a lipidated peptide like Cagrilintide follows the same underlying methods used across Amino Line's catalog, applied with additional resolution requirements. Reverse-phase HPLC is used to establish purity and to resolve lipidation-related impurities — species missing the fatty-acid conjugate, species with conjugation at an incorrect site, or aggregated material — from the target compound. Mass spectrometry, typically electrospray ionization coupled to time-of-flight or quadrupole detection, confirms the intact mass of the lipidated species against the calculated molecular weight, verifying that both the peptide backbone and the conjugation are correct.
Circular dichroism and related biophysical methods are used in the broader amylin-analog literature to assess secondary structure and aggregation state, given native amylin's well-documented amyloidogenic behavior. Confirming that a lipidated analog does not retain problematic aggregation kinetics is a meaningful component of research-grade characterization for this compound class, distinct from the purity and identity metrics alone.
Batch-specific Certificates of Analysis documenting these results accompany each unit Amino Line supplies, consistent with the documentation standard applied across the catalog regardless of a compound's synthesis complexity.
What research contexts has Cagrilintide appeared in?
Cagrilintide is studied primarily in contexts examining amylin receptor complex pharmacology and, in combination research designs, alongside GLP-1 receptor-targeted compounds to examine multi-receptor signaling architecture. Because AMY receptor complexes and GLP-1R are both class B GPCRs relevant to pancreatic and energy-homeostasis signaling circuitry in studied model systems, research panels have used Cagrilintide alongside GLP-1R agonists to characterize signaling interactions between the two receptor axes under matched experimental conditions.
Structural biology contexts using cryo-EM and related methods to resolve amylin receptor complex conformations have used stabilized amylin analogs including Cagrilintide as tractable ligands for structural work, given the handling limitations of native amylin. Receptor internalization and desensitization kinetics following amylin receptor complex activation have also been characterized using long-acting analogs, where the extended half-life relative to native amylin allows observation windows not accessible with the native hormone.
Amino Line does not make therapeutic or outcome claims regarding Cagrilintide in any of these contexts. The compound is studied at the level of receptor binding, signaling, and structural characterization in laboratory model systems.
How should Cagrilintide be stored and handled for research?
Cagrilintide is supplied as a lyophilized powder and stored at −20°C to preserve structural integrity. As a lipidated peptide, it carries the same general degradation vulnerabilities as other synthetic peptides — oxidation, moisture-induced hydrolysis, thermal denaturation — alongside handling considerations specific to the fatty-acid conjugate, including sensitivity to conditions that promote micelle formation or aggregation in solution. Repeated freeze-thaw cycles increase cumulative exposure to these degradation pathways and are avoided in best-practice research handling.
Cold-chain shipping protects material integrity during transit, and Amino Line ships all peptide compounds, including Cagrilintide, with cold-chain packaging as standard. This article does not provide handling or preparation protocols; those are determined by the researcher according to experimental requirements and applicable regulations.
How does Amino Line source and catalog Cagrilintide?
Amino Line supplies Cagrilintide as a research-grade compound characterized by HPLC purity analysis and mass spectrometry identity confirmation, with batch-specific Certificates of Analysis available for every order. All shipments are cold-chain packaged as standard, and operations are US-based.
Cagrilintide extends Amino Line's structural characterization catalog into lipidated analog compounds, evaluated to the same analytical documentation standard applied to the classic heritage compounds the catalog was built on. Related research compounds are available at all compounds. All material is for laboratory research use only and is not for human use.
This compound is a research chemical intended for laboratory and scientific research purposes only. It is not a drug, supplement, or food product, and is not intended to diagnose, treat, cure, or prevent any disease. Amino Line does not sell products intended for human use. Researchers are responsible for compliance with all applicable local, state, and federal regulations.
